28095 Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment

Andrew Blauvelt; Kenneth B. Gordon; Christopher Em Griffiths; Kim Papp; Peter Foley; Michael Song; Megan Miller; Yaung‐Kaung Shen; Paraneedharan Ramachandran; Kristian Reich

doi:10.1016/j.jaad.2021.06.708

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2019

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials

Kristian Reich, Christopher Em Griffiths, Kenneth B. Gordon, Kim Papp, Michael Song, B. Randazzo, Shu Li, Yaung‐Kaung Shen, Chenglong Han, Alexa B. Kimball, April W. Armstrong, Peter Foley, Andrew Blauvelt

Article2019

Maintenance of Response With up to 4 Years of Continuous Guselkumab Treatment: Results From the VOYAGE 1 Phase 3 Trial

Christopher Em Griffiths, Kim Papp, Mengsa Song, Megan Miller, Yin You, Y-K Shen, Chenglong Han, Andrew Blauvelt

Article2018

Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.

Christopher Em Griffiths, Kim Papp, Alexa B. Kimball, B. Randazzo, Michael Song, Shu Li, Yaung‐Kaung Shen, Andrew Blauvelt

Article2021

AB0532 MAINTENANCE OF RESPONSE THROUGH 5 YEARS OF CONTINUOUS GUSELKUMAB TREATMENT: RESULTS FROM THE PHASE-3 VOYAGE 1 TRIAL

Christopher Em Griffiths, Kim Papp, Michael Song, Megan Miller, Yin You, Yaung‐Kaung Shen, Andrew Blauvelt

Article2018

Secukinumab's Pooled and Long-Term Safety: Analysis of 19 Psoriasis Clinical Trials Up to 5 Years of Treatment

PCM van de Kerkhof, Kristian Reich, C Leonardi, Andrew Blauvelt, Nehal Nailesh Mehta, TF Tsai, R. You, Phil Papanastasiou, M. Milutinovic, Christopher Em Griffiths